The vaccine development process by Bharat Biotech, Biological E Ltd and Aurobindo Pharma are currently in various stages, while Dr Reddy's and Hetero have tie ups for manufacturing the vaccine

In India, RDIF has tied up with Dr Reddy's Laboratories for trials and regulatory approvals. Dr Reddy's recently began phase-2 and 3 clinical trials after getting requisite clearance

 India readies for 60 crore doses of Covid-19 vaccines to be administered to the most vulnerable people through conventional cold chain systems, says top government expert

As the country plans to vaccinate 30 crore people by July in the first phase, it may be difficult to bank alone on the Indian vaccines, especially Serum Institute's (SII) Covishield

Sputnik V in India: India's Dr Reddy's Laboratories and Hetero Drugs have a license to sell 100 million doses of the vaccine in India and limited trials are also being done in the country, as part of the approval process

There are only five companies that have given preliminary data about how effective their vaccines could be to fight against coronavirus. These five companies include Pfizer-BioTech, Moderna Inc, Oxford University-AstraZeneca Plc, and Gamaleya Institute

Prime Minister Narendra Modi's visit to these facilities and discussions with the scientists are to help him get a first-hand perspective of the preparations, challenges and roadmap in India's vaccination plans

The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries. The safety of vaccines based on human adenoviruses has been confirmed in more than 75 international publications and in more than 250 clinical trials.

The company could be looking at manufacturing 100 million doses to begin with, as per Chairman Pankaj Patel.

The total 39 positive cases were those reported at various points including Sannidhanam (temple complex) and Pamba and Nilakkal, the base camps

India assured the people of Nepal that once it rolls out a vaccine against COVID-19, meeting their requirement will be a priority for New Delhi, amid a spike of the deadly disease in the Himalayan nation

British-Swedish pharma giant AstraZeneca Plc is hoping for the new test to substantiate the 90 per cent efficacy rate the inoculation demonstrated in a portion of an ongoing trial

\"I'm telling you, I'm not going to take it. It's my right,\" news agency Reuters quoted Bolsonaro as saying.

Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021

The WHO said that the Solidarity trial looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients

Tata Consultancy Services has announced a salary hike for its employees effective October 1; The World Bank has warned that by 2021, as many as 150 million people are likely to be in extreme poverty because of the coronavirus pandemic; Chinese gaming app PUBG Mobile is reportedly talking to telecom major Bharti Airtel to bring the popular multiplayer game back on the mobile screens of its Indian fans. Watch this and more on News Blast.Also Read: Hetero plans to make COVID-19 drug Favipiravir in injection form

Last month, Hetero became the first Indian drug company to launch Favipiravir in 800/200mg dosage for the treatment of mild-to-moderate symptomatic Covid-19 patients

Chemcon Speciality Chemicals IPO: The specialised chemical products manufacturer is offering 93.52 lakh shares of Rs 10 each

Chemcon Speciality Chemicals IPO: Price band for the IPO has been fixed at Rs  338 to Rs 340 per share

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical